El interés en corto de Rimini Street da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Rimini Street. Los datos de interés en corto se actualizan cada dos semanas.

Rimini Street (NASDAQ:RMNI) Bolsa, Informe de interés en corto

Rimini Street

Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The Company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, database, and technology software platforms. The Company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management database, and technology software systems. Geographically, the company generates the majority of its revenue from the United States of America and the International market.

Rimini Street Inc

<p>RBC Capital Markets analyst <strong>Nik Modi</strong> reiterated the Sector Perform rating on <strong>Campbell&#8217;s Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>), lowering the price forecast to $44 from $51.</p>
<p>Yesterday, the company reported second-quarter sales growth of 9% to $2.685 billion, <a target="_blank" href="https://www.benzinga.com/25/03/44140506/campbells-stocks-fall-on-q2-sales-miss-and-gloomy-outlook" rel="noreferrer noopener">missing the analyst&nbsp;consensus estimate of $2.74 billion.</a></p>
<p>For FY25, Campbell&nbsp;sees net sales growth of 6% to 8% (prior view: 9%&nbsp;to&nbsp;11%). Adjusted EBIT growth<strong>&nbsp;</strong>of 3% to 5% (previous view: 9%&nbsp;to&nbsp;11%).</p>
<p>Modi suggests that while Campbell&#8217;s challenging results and full-year guidance cut were anticipated, the company made a wise decision to address these issues upfront, allowing them to focus on performance improvements despite ongoing macro and consumer challenges.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/03/44171189/whats-going-on-with-exxon-mobil-xom-shares" rel="noreferrer noopener">What&#8217;s Going On With Exxon Mobil (XOM) Shares?</a></strong></p>
<p>Additionally, Campbell&#8217;s Company is considered undervalued compared to its peers and historical performance, though the analyst stresses that further efforts are needed before the stock can see positive movement.</p>
<p>The analyst states in response to F2Q results, estimates were adjusted for FY25 net sales growth to +6.7% (prior view: +9.2%), organic sales growth to -1.2% (prior view: +0.4%), EBIT growth to +9.2% (prior view: from +3.2%) and EPS to $2.99 (prior view: $3.17).</p>
<p>Per the analyst, lowering the full-year guidance was the right move, but due to the fluid environment, Modi remains cautious and slightly below the midpoint of the company&#8217;s top-line guidance, anticipating consumer sentiment could &#8220;soften&#8221; further.</p>
<p><strong>CPB Price Action: </strong>Campbell&#8217;s Co. shares are trading higher by 0.61% to $39.40 at last check Thursday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/government/regulations/25/03/44171377/retailers-warn-of-price-increases-due-to-trump-tariffs-as-consumer-health-concerns-persist" target="_blank" rel="noreferrer noopener">Retailers Warn Of Price Increases Due To Trump Tariffs As Consumer Health Concerns Persist</a></strong></li>
</ul>
<p><em>Photo: JHVEPhoto via Shutterstock</em></p>


Equities

News

Price Target

Reiteration

Analyst Ratings

Trading Ideas

General

Campbell's Faces Slower Growth: Analyst Cuts Price Forecast As Consumer Sentiment Could Weaken Further

<p>HC Wainwright has initiated coverage on <strong>ImmunityBio, Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>). The company's lead asset is Anktiva (nogapendekin alfa inbakicept-pmln) solution for intravesical use, approved by the Food and Drug Administration indicated with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive bladder carcinoma in situ (CIS) with or <a href="https://www.benzinga.com/general/biotech">without papillary tumors</a>.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43038889/immunitybio-stock-trading-higher-on-updates-from-bladder-cancer-trials-details" rel="noreferrer noopener">ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details</a></strong></p>
<p>HC Wainwright analyst Andres Y. Maldonado writes that Anktiva will follow a different market path than the two latest FDA-approved treatments for high-risk bladder cancer—<strong>Merck &amp; Co Inc's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda and <strong>Ferring Pharmaceutical's</strong> Adstiladrin—both of which have faced hurdles after launch.</p>
<p>Keytruda's adoption has been slow because urologists are hesitant to refer patients to oncologists and worry about its side effects. Adstiladrin, on the other hand, has struggled with supply issues, though Ferring says availability has recently improved.</p>
<p>HC Wainwright projects 2025 Anktiva revenue of $137.4 million, growing to $4.3 billion by 2034. The analyst has initiated with a Buy rating <a href="https://www.benzinga.com/quote/IBRX/analyst-ratings" target="_blank" rel="noreferrer noopener">and an $8 price target</a>.</p>
<p>In the fourth quarter, ImmunityBio reported <a href="https://www.benzinga.com/pressreleases/25/03/b44073991/immunitybio-reports-sales-momentum-unit-growth-since-permanent-j-code-issuance-j9028-in-january-20">product revenue of $7.21 million</a> and $14.2 million in the fiscal year 2024. The increase was driven by sales of ANKTIVA after FDA <a href="https://www.benzinga.com/general/biotech/24/04/38380405/fda-approves-immunitybios-bladder-cancer-drug-stock-rallies" target="_blank" rel="noreferrer noopener">approval in April 2024</a>.</p>
<p>Recently, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for Anktiva and CAR-NK (PD-L1 t-haNK) for the reversal of lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy and in multiply relapsed locally advanced or <a target="_blank" href="http://lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy and in multiply relapsed locally advanced or metastatic pancreatic cancer." rel="noreferrer noopener">metastatic pancreatic cancer</a>.</p>
<p>While many are watching the competition between <strong>CG Oncology Inc's</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) cretostimogene and <strong>Johnson &amp; Johnson's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) TAR-200 in the NMIBC market, Anktiva stands out with a first-mover advantage in a market potentially worth over $5 billion, the analyst says.</p>
<p>&#8220;Ultimately, we believe ANKTIVA's profile coupled with ease of administration will weigh more heavily in treatment decisions than comparisons of complete response (CR) rates at various time points to unapproved products,&#8221; the analyst writes.</p>
<p><strong>Price Action:</strong> IBRX stock is down 2.47% at $2.98 at last check Thursday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/government/regulations/25/03/44169989/federal-judge-halts-national-institutes-of-healths-grant-policy-overhaul-citing-legal-violations" target="_blank" rel="noreferrer noopener">Federal Judge Halts National Institutes of Health&#8217;s Grant Policy Overhaul Citing Legal Violations</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Analyst Color

Biotech

Health Care

Initiation

CGON

IBRX

ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug

Macro Economic Events

Global

Economics

President Trump's Special Envoy Witkoff Says In Discussions To Coordinate Meeting With Ukraine In Saudi Arabia; Trying To Get A Framework For Peace Agreement And Initial Ceasefire For Ukraine

STLA

TSLA

Mexico President Claudia Sheinbaum Says We Want A Good Part Of Auto Makers' Production In Mexico To Be For Local Market

<p>B of A Securities  analyst Allen Lutz   reiterates Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Underperform and maintains $21 price target.</p>


Hims & Hers Health, Inc. Class A Common Stock

HIMS

B of A Securities Reiterates Underperform on Hims & Hers Health, Maintains $21 Price Target

<p>Alliance Global Partners  analyst James Molloy   reiterates IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) with a Buy and maintains $3.5 price target.</p>


Alliance Global Partners Reiterates Buy on IGC Pharma, Maintains $3.5 Price Target

<p>American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) today announced that it has entered into an agreement to acquire <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fgetcenter.com&amp;esheet=54220394&amp;newsitemid=20250306154813&amp;lan=en-US&amp;anchor=Center&amp;index=1&amp;md5=31f976a9bf2007ec4f13a62801dc8cb7">Center</a>,a software company modernizing expense management.</p>
<p>This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20250306154813/en/">https://www.businesswire.com/news/home/20250306154813/en/</a></p>
<p>Center's software, together with American Express' corporate and small business cards, will aim to create a seamless expense management platform that delivers more value across the commercial card payments process – from choice in premium card offerings and rewards to automated accounting and reconciliation.</p>


American Express To Acquire Center, A Software Company Modernizing Expense Management; No Financial Terms Disclosed

<p>Across the recent three months, 20 analysts have shared their insights on Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $89.85, along with a high estimate of $115.00 and a low estimate of $80.00. Observing a downward trend, the current average is 1.75% lower than the prior average price target of $91.45. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741284100_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Uber Technologies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$92.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$107.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Wolfe Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Buy</td>
<td>$96.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Uber Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Uber Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Uber Technologies's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Uber Technologies's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UBER/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Uber Technologies analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Uber Technologies</h2>
<p>Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars as well as autonomous vehicles, but could eventually be used for additional products and services, such as delivery via drones or electronic vehicle take-off and landing (eVTOL) technology. Uber operates in over 70 countries, with over 171 million users who order rides or food at least once a month.</p>
<h3>Uber Technologies: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Uber Technologies showcased positive performance, achieving a revenue growth rate of <strong>20.36%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>57.55%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Uber Technologies's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>37.88%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Uber Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>14.0%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Uber Technologies's debt-to-equity ratio is below the industry average. With a ratio of <b>0.52</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


UBER

20 Analysts Assess Uber Technologies: What You Need To Know

<p>In the preceding three months, 4 analysts have released ratings for Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $6.12, a high estimate of $7.00, and a low estimate of $4.50. This upward trend is evident, with the current average reflecting a 11.27% increase from the previous average price target of $5.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741284093_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Riskified. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$4.50</td>
<td>$4.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$7.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Riskified. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Riskified compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into Riskified's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RSKD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Riskified analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Riskified: A Closer Look</h2>
<p>Riskified Ltd has built a next-generation eCommerce risk management platform that allows online merchants to create trusted relationships with their consumers. It generates revenue by granting merchants access to its eCommerce risk management platform and reviewing and approving eCommerce transactions for legitimacy. Its merchants include some of the ecommerce brands including Wayfair, Lastminute.com, SHEIN, and Macy's. Its merchants operate in a variety of verticals, including Payments, Money Transfer &amp; Crypto, Tickets &amp; Travel, Electronics, Home, Fashion &amp; Luxury Goods, General Retail and Food. The company derived maximum revenue from Israel.</p>
<h3>Key Indicators: Riskified's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Riskified displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>9.71%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-12.3%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Riskified's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-2.34%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Riskified's ROA excels beyond industry benchmarks, reaching <strong>-1.88%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Riskified's debt-to-equity ratio is below the industry average at <strong>0.07</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RSKD

Beyond The Numbers: 4 Analysts Discuss Riskified Stock

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Oklo</strong>.</p>
<p>Looking at options history for Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) we detected 17 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 23% of the investors opened trades with bullish expectations and 64% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $349,004 and 10, calls, for a total amount of $693,006.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $15.0 to $60.0 for Oklo over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Oklo options trades today is 698.07 with a total volume of 3,783.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Oklo's big money trades within a strike price range of $15.0 to $60.0 over the last 30 days.</p>
<h3>Oklo Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741284082_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$6.55</td>
<td>$6.2</td>
<td>$6.55</td>
<td>$28.00</td>
<td>$197.4K</td>
<td>364</td>
<td align="right">302</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.7</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$26.00</td>
<td>$179.2K</td>
<td>1.4K</td>
<td align="right">13</td>
</tr>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$6.75</td>
<td>$6.55</td>
<td>$6.7</td>
<td>$30.00</td>
<td>$88.4K</td>
<td>744</td>
<td align="right">342</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.5</td>
<td>$8.05</td>
<td>$8.1</td>
<td>$40.00</td>
<td>$63.1K</td>
<td>2.4K</td>
<td align="right">88</td>
</tr>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.45</td>
<td>$1.44</td>
<td>$1.45</td>
<td>$24.00</td>
<td>$59.7K</td>
<td>426</td>
<td align="right">412</td>
</tr>
</tbody>
</table>
</p>
<h3>About Oklo</h3>
<p>Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.</p>
<p>Having examined the options trading patterns of Oklo, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Oklo Standing Right Now?</h3>
<ul>
<li>With a volume of 7,959,658, the price of OKLO is down -11.32% at $26.86. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 18 days.</li>
</ul>
<h3>Expert Opinions on Oklo</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $58.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on Oklo, maintaining a target price of $58. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Oklo, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

OKLO

Behind the Scenes of Oklo's Latest Options Trends

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>McDonald's</strong>.</p>
<p>Looking at options history for McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) we detected 8 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 50% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $120,210 and 5, calls, for a total amount of $218,875.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $270.0 to $310.0 for McDonald's during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of McDonald's stands at 1242.29, with a total volume reaching 220.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in McDonald's, situated within the strike price corridor from $270.0 to $310.0, throughout the last 30 days.</p>
<h3>McDonald's Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741284077_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MCD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$12.15</td>
<td>$11.75</td>
<td>$11.75</td>
<td>$310.00</td>
<td>$58.7K</td>
<td>251</td>
<td align="right">55</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$6.3</td>
<td>$5.45</td>
<td>$5.8</td>
<td>$305.00</td>
<td>$58.0K</td>
<td>2.0K</td>
<td align="right">101</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$48.1</td>
<td>$47.7</td>
<td>$48.1</td>
<td>$275.00</td>
<td>$57.7K</td>
<td>805</td>
<td align="right">7</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$62.95</td>
<td>$62.05</td>
<td>$62.05</td>
<td>$270.00</td>
<td>$43.4K</td>
<td>226</td>
<td align="right">8</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.3</td>
<td>$5.45</td>
<td>$5.99</td>
<td>$305.00</td>
<td>$32.9K</td>
<td>2.0K</td>
<td align="right">101</td>
</tr>
</tbody>
</table>
</p>
<h3>About McDonald's</h3>
<p>McDonald's is the largest restaurant owner-operator in the world, with 2024 system sales of $131 billion across more than 43,000 stores and 115 markets. McDonald's pioneered the franchise model, building its footprint through partnerships with independent restaurant franchisees and master franchise partners around the globe. The firm earns roughly 60% of its revenue from franchise royalty fees and lease payments, with most of the remainder coming from company-operated stores across its three core segments: the United States, internationally operated markets, and international developmental/licensed markets.</p>
<h3>McDonald's's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,031,694, the price of MCD is up by 0.45%, reaching $308.83.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 54 days from now.</li>
</ul>
<h3>Expert Opinions on McDonald's</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $326.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Baird has decided to maintain their Neutral rating on McDonald's, which currently sits at a price target of $310.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on McDonald's, which currently sits at a price target of $300.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on McDonald's with a target price of $350.<br />
&#x2A; Maintaining their stance, an analyst from Wedbush continues to hold a Outperform rating for McDonald's, targeting a price of $330.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on McDonald's, which currently sits at a price target of $340. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest McDonald's options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


McDonald's Unusual Options Activity

<p>Analysts' ratings for 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated 3M and provided 12-month price targets. The average target is $147.0, accompanied by a high estimate of $179.00 and a low estimate of $96.00. This current average has increased by 3.52% from the previous average price target of $142.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741284076_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive 3M is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$179.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$96.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$96.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$162.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$161.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$96.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to 3M. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of 3M compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for 3M's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of 3M's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MMM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on 3M analyst ratings.</strong></a></p>
<h2>About 3M</h2>
<p>3M, a multinational conglomerate founded in 1902, sells tens of thousands of products ranging from sponges to respirators. The firm is well known for its extensive research and development capabilities, and it is a pioneer in inventing new use cases for its proprietary technologies. 3M is organized across three business segments: safety and industrial (representing around 44% of revenue), transportation and electronics (36%), and consumer (20%). The firm recently spun off its healthcare business, now known as Solventum. Nearly half of 3M's revenue comes from outside the Americas.</p>
<h3>3M: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> 3M's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>0.13%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> 3M's net margin is impressive, surpassing industry averages. With a net margin of <strong>12.11%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> 3M's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>17.16%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> 3M's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.8%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>3.56</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 11 Analysts Discuss 3M Stock

<p>High-rolling investors have positioned themselves bullish on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ABT often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 11 options trades for Abbott Laboratories. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 72% bullish and 9% bearish. Among all the options we identified, there was one put, amounting to $41,820, and 10 calls, totaling $728,484.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $115.0 to $145.0 for Abbott Laboratories over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Abbott Laboratories's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Abbott Laboratories's substantial trades, within a strike price spectrum from $115.0 to $145.0 over the preceding 30 days.</p>
<h3>Abbott Laboratories 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741284072_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$22.25</td>
<td>$21.95</td>
<td>$22.25</td>
<td>$115.00</td>
<td>$277.9K</td>
<td>1.2K</td>
<td align="right">127</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$3.65</td>
<td>$3.05</td>
<td>$3.65</td>
<td>$132.00</td>
<td>$91.2K</td>
<td>202</td>
<td align="right">1</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$17.55</td>
<td>$16.45</td>
<td>$16.95</td>
<td>$120.00</td>
<td>$83.0K</td>
<td>533</td>
<td align="right">49</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$5.8</td>
<td>$5.75</td>
<td>$5.8</td>
<td>$145.00</td>
<td>$73.6K</td>
<td>321</td>
<td align="right">128</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.85</td>
<td>$6.7</td>
<td>$6.85</td>
<td>$135.00</td>
<td>$45.2K</td>
<td>1.1K</td>
<td align="right">235</td>
</tr>
</tbody>
</table>
</p>
<h3>About Abbott Laboratories</h3>
<p>Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.</p>
<h3>Abbott Laboratories's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,532,529, the price of ABT is down by -2.37%, reaching $134.44.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 41 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Abbott Laboratories</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $157.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Abbott Laboratories, which currently sits at a price target of $160.<br />
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Abbott Laboratories, targeting a price of $154. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Abbott Laboratories with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment

JEPI

PAYX

CNBC Halftime Report Final Trades: Paychex, Pfizer, JPMorgan Equity Premium Income ETF

<p>8 analysts have shared their evaluations of State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $121.0, a high estimate of $139.00, and a low estimate of $103.00. Marking an increase of 4.7%, the current average surpasses the previous average price target of $115.57. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741284070_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of State Street by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$139.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$103.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$104.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$106.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$127.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$132.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$139.00</td>
<td>$102.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to State Street. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of State Street compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of State Street's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into State Street's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/STT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on State Street analyst ratings.</strong></a></p>
<h2>Delving into State Street's Background</h2>
<p>State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $47 trillion in assets under custody and administration and $4.7 trillion assets under management as of Dec. 31, 2024, State Street operates globally in more than 100 geographic markets and employs about 53,000 worldwide.</p>
<h3>Key Indicators: State Street's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> State Street's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>12.13%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> State Street's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>21.34%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>3.2%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> State Street's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.21%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> State Street's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.47</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down State Street: 8 Analysts Share Their Views

<p>Throughout the last three months, 8 analysts have evaluated Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Waters, presenting an average target of $419.38, a high estimate of $450.00, and a low estimate of $390.00. This upward trend is evident, with the current average reflecting a 4.1% increase from the previous average price target of $402.86.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741284062_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Waters by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$390.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$450.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$420.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$410.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$410.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$415.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$430.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$430.00</td>
<td>$400.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Waters. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Waters compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into Waters's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WAT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Waters analyst ratings.</strong></a></p>
<h2>All You Need to Know About Waters</h2>
<p>Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.</p>
<h3>Key Indicators: Waters's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Waters's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>6.5%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Waters's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>26.51%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Waters's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>13.49%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>5.11%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Waters's debt-to-equity ratio is below the industry average at <strong>0.93</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


8 Analysts Have This To Say About Waters

<p>U.S. stocks were lower, with the Dow Jones falling over 500 points on Thursday.</p>
<p>Shares of <strong>BJ&#8217;s Wholesale Club Holdings, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) rose sharply during Thursday's session after the company reported better-than-expected <a href="https://in.benzinga.com/news/earnings/25/03/44165337/bjs-wholesale-club-posts-q4-earnings-above-street-view-due-to-strong-membership-fee">fourth-quarter financial results</a>.</p>
<p>The company reported a fourth-quarter revenue decline of 1.4% year-on-year to $5.28 billion, beating the analyst consensus estimate of $5.27 billion. Adjusted EPS of 93 cents beat the consensus estimate of 87 cents.</p>
<p>Workday shares jumped 13.1% to $113.15 on Thursday.</p>
<p>Here are some other big stocks recording gains in today's session.</p>
<ul>
<li><strong>Myers Industries, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) shares surged 25.3% to $12.20 after the company reported better-than-expected quarterly financial results.</li>
<li><strong>LendingTree, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) shares jumped 25% to $50.35 after the company reported better-than-expected fourth-quarter financial results.</li>
<li><strong>Studio City International Holdings Limited</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSC#NYSE">MSC</a>) gained 18.6% to $3.2750.</li>
<li><strong>America&#8217;s Car-Mart, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMT#NASDAQ">CRMT</a>) rose 16.9% to $44.85 after the company reported upbeat quarterly financial results.</li>
<li><strong>John Wiley &amp; Sons, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) gained 13.5% to $43.03 following better-than-expected quarterly financial results.</li>
<li><strong>Burlington Stores, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) rose 9.9% to $260.50 after the company reported better-than-expected fourth-quarter financial results.</li>
<li><strong>Veeva Systems Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) gained 9% to $239.73 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
<li><strong>Viking Therapeutics, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) rose 6.8% to $29.84.</li>
<li><strong>Polaris Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) gained 4.9% to $43.25.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></strong></li>
</ul>


Intraday Update

BURL

CRMT

TREE

VEEV

VKTX

BJ's Wholesale Club Posts Better-Than-Expected Earnings, Joins Burlington Stores, Veeva Systems And Other Big Stocks Moving Higher On Thursday

<p>Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Teva Pharmaceutical Indus, presenting an average target of $26.83, a high estimate of $30.00, and a low estimate of $20.00. Witnessing a positive shift, the current average has risen by 2.52% from the previous average price target of $26.17.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741284051_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Teva Pharmaceutical Indus among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teva Pharmaceutical Indus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Teva Pharmaceutical Indus's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Teva Pharmaceutical Indus's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TEVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Teva Pharmaceutical Indus analyst ratings.</strong></a></p>
<h2>Delving into Teva Pharmaceutical Indus's Background</h2>
<p>Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.</p>
<h3>Teva Pharmaceutical Indus: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Challenges:</strong> Teva Pharmaceutical Indus's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-5.12%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Teva Pharmaceutical Indus's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-5.13%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Teva Pharmaceutical Indus's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-3.79%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Teva Pharmaceutical Indus's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-0.54%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Teva Pharmaceutical Indus's debt-to-equity ratio surpasses industry norms, standing at <strong>3.36</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TEVA

Forecasting The Future: 6 Analyst Projections For Teva Pharmaceutical Indus

<p>What does it <a href="https://www.benzinga.com/money/are-you-rich">really mean to be rich</a>? For some, it's about feeling financially secure—being able to afford the life they want without stress. For others, it's about reaching a specific benchmark, like being in the top 5% of households by net worth. If you're wondering where you stand, the Federal Reserve has the numbers to tell you exactly how much wealth it takes to join the ranks of the financially elite.</p>
<h2 class="wp-block-heading">How Wealth Is Measured</h2>
<p>Every three years, the Federal Reserve conducts the <a href="https://www.federalreserve.gov/econres/scfindex.htm">Survey of Consumer Finances</a>, a deep dive into the wealth, debt, and income of American households. The latest data, collected in 2022, gives us the most up-to-date look at household net worth. The next update won't be <a href="https://www.federalreserve.gov/newsevents/pressreleases/other20250228a.htm">until 2026</a>, so for now, these numbers are the best benchmark we have.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></strong></li>
<li><strong><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a></strong><strong> Here&#8217;s what Americans think you need to be considered wealthy.</strong></li>
</ul>
<p>If you want to be in the top 5% of households, you'd need a net worth of $3.795 million. However, this number varies significantly by age. Younger households need much less to break into the top 5%, while older households require much more due to decades of wealth accumulation.</p>
<h2 class="wp-block-heading">Net Worth Needed for Top 5% by Age</h2>
<p>Here's a breakdown of the net worth needed to be in the top 5% by age group:</p>
<p>Ages 18 to 29: A net worth of at least $415,700</p>
<p>Ages 30 to 39: A net worth of at least $1,104,100</p>
<p>Ages 40 to 49: A net worth of at least $2,551,500</p>
<p>Ages 50 to 59: A net worth of at least $5,001,600</p>
<p>Ages 60 to 69: A net worth of at least $6,684,220</p>
<p>Ages 70 and older: A net worth of at least $5,860,400</p>
<p>Net worth tends to climb the most in your 40s and 50s, when career earnings peak and investments have had time to grow.&nbsp;</p>
<p><strong>Trending: <a href="https://www.benzinga.com/money/millionaires-never-earned-six-figures-according-to-dave-ramsey"><strong>69% of Millionaires Never Earned A Six-Figure Salary – Here Are 2 Things They Do To Get Their First $1 Million, According To Dave Ramsey</strong></a></strong></p>
<h2 class="wp-block-heading">Does a High Income Guarantee Wealth?</h2>
<p>While earning a high income can certainly help build wealth, it's not a guarantee. The Federal Reserve's survey shows that many top earners don't have a <a href="https://www.benzinga.com/personal-finance/25/02/43539942/are-you-rich-heres-what-americans-think-you-need-to-be-considered-wealthy-2">net worth that puts them in the top 5%</a>.</p>
<p>For example, only 32% of top earners in their 20s have a high enough net worth to rank in the top 5%. That number climbs to just over 50% for those in their 30s and 40s and increases even further for older households.</p>
<p>The reason? Spending habits and investment strategies play a massive role in long-term wealth accumulation. Simply earning more doesn't mean much if you don't save and invest wisely.</p>
<p><strong><em>See Also: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"><strong><em> The percentage may shock you</em></strong></a>.</em></strong></p>
<h2 class="wp-block-heading">What Does This Mean for Married Couples Trying to Build Wealth?</h2>
<p>For couples striving to build wealth, hitting a specific net worth benchmark is just one piece of the puzzle. You could have millions in assets but feel less financially secure than someone with a lower net worth and minimal expenses. True financial well-being comes from managing debt, maintaining a sustainable lifestyle, and making smart investment choices that align with long-term goals.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></strong></li>
<li><strong>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"><strong> </strong><strong>Tax deferring is their number one strategy</strong></a>.</strong></li>
</ul>


Personal Finance

Are You a Rich Couple? Here's the Net Worth You Need to Be Wealthier Than 95% of Households

<p><strong>LendingTree, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) shares are trading higher on Thursday after the company reported better-than-expected fourth-quarter financial <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44154278/lendingtree-stock-rallies-after-strong-q4-results-details" rel="noreferrer noopener">results after-hours yesterday</a>.</p>
<p>The company reported earnings of&nbsp;$1.16&nbsp;per share, which beat the analyst consensus estimate of losses of five cents, and revenue came in at&nbsp;$261.5 million,&nbsp;which beat the analyst <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus estimate of&nbsp;$236.84 million</a>.</p>
<p>LendingTree sees&nbsp;first-quarter revenue in a range of $241 million to $248 million, versus the&nbsp;$243.27 million&nbsp;analyst estimate. The company sees fiscal 2025 revenue in a range of $985 million to $1.025 <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">billion versus the $1.02 billion estimate</a>.</p>
<p><strong>J.P. Morgan </strong>analyst Melissa Wedel raised the price forecast from $65.00 to $68.00 <a target="_blank" href="https://www.benzinga.com/quote/tree/analyst-ratings" rel="noreferrer noopener">while keeping an Overweight rating</a>.</p>
<p>The analyst forecasts double-digit year-over-year growth across all segments, with a slight margin increase for Home and Insurance, and a small margin decrease for Consumer segments.</p>
<p>Wedel says that the fourth-quarter performance exceeded estimates and guidance, which is certainly a positive, along with expected revenue growth across all segments.</p>
<p>Meanwhile, it&#8217;s worth noting that the FY25 revenue and adjusted EBITDA guidance aligned with consensus estimates ahead of the earnings report, adds the analyst.</p>
<p>The analyst says that 2025 seems to mark the long-anticipated return to growth across all business segments despite lenders maintaining strict underwriting standards.</p>
<p>The analyst says that she remains confident that as SPRING (formerly MyLendingTree) expands and introduces more features, it will generate additional revenue across its product offerings in the long term.</p>
<p>Other price forecast revisions include:</p>
<ul>
<li><strong>Keefe, Bruyette &amp; Woods</strong> analyst Ryan Tomasello reaffirmed an Outperform and lowered the price forecast from $73 to $66.</li>
<li><strong>Needham </strong>analyst Mayank Tandon maintained a Buy rating and slashed the price forecast from $78 to $65.</li>
</ul>
<p><strong>Price Action</strong>: TREE shares are up 23.7% at $49.83 at the last check Thursday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/03/44166208/palantir-and-eysa-join-forces-to-revolutionize-urban-mobility-management" target="_blank" rel="noreferrer noopener">Palantir, EYSA Join Forces To Power Urban Mobility Management: Details</a></strong></li>
</ul>
<p><em>Image: Shutterstock/ Bigc Studio.</em></p>


Small Cap

Movers

LendingTree Surges On Strong Q4 Results, Analysts Sees 'Long-Awaited Return Of Growth' In 2025

Press Releases

Rimini Street Announces Expansion of its Database Security Solutions Providing Even More Extensive Security and Compliance Capabilities for Most Common Commercial and Open-Source Databases

GRP Partners with Rimini Street to Support its S/4HANA Systems and Smart Factory Project

Rimini Street Announces New Management Console for Rimini Connect™ Suite of Interoperability Solutions

New Survey of VMware Customers Reveals Strong Desire to Maximize the Value of Perpetual Licenses

Rimini Street Honored by Clients and Industry with Buyer's Choice, Service and Leadership Awards

Rimini Street Announces Rimini Protect™ Advanced Hypervisor Security for VMware, Nutanix and All Other Linux-Based Hypervisors, Powered by Vali Cyber®, to Safeguard Against Ransomware and Other Vulnerabilities

Rimini Street to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27, 2025

Rimini Street Celebrates the 10th Anniversary of its Corporate Foundation with a $100,000 RMNI LOVE Charitable Grant Giveaway

Rimini Street Announces Fiscal Fourth Quarter and Annual 2024 Financial and Operating Results

Rimini Street and T-Systems North America Announce a Strategic Partnership to Deliver Comprehensive, Cost-Effective Enterprise Software Support and Hosting Solutions

RMNI

Agora

Digital Turbine

Bit Digital

Consensus Cloud Solutions, Inc. - Common Stock

Consensus Cloud Solns

Cerence

Digimarc

Domo

Viant Technology

Expensify

Helport AI

Kaltura

CS Disco

Logility Supply Chain Solutions, Inc. - Common Stock

Logility Supply Chain

Mercurity Fintech Holding Inc. - American Ordinary Shares

Mercurity Fintech Holding

Mitek Systems

Materialise NV - American Depositary Shares

Materialise

OneConnect Financial Technology Co., Ltd. American Depositary Shares, each representing thirty ordinary shares

Comments

Rimini Street

Interés en corto

Rimini Street (NASDAQ:RMNI) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL